Endotoxin and Clone

Dr / Ing. Method of production of drugs: an aerosol for inhalation, dosed 1 mg / dose to 112 or 200 doses in the cylinders, 5 mg / dose 112 doses in bottled. Mr for oral application, 1mh/ml. The main pharmaco-therapeutic effects: membrane stabilizer of mast cells in vivo inhibits the immediate hypersensitivity reaction type I; suppresses increased vascular permeability surface associated with reahinom or IgE here a / g - induced reactions, can stabilize the mast cells of rodents and prevent the induction and / g the release of histamine, mast cells prevents the release of other refresh rate of inflammation and inhibits eosinophil chemotaxis; refresh rate drug substance prevents the flow of calcium ions in refresh rate cells after stimulation and / G is not pronounced vasoconstrictor, antihistaminic effect as that inhibits cyclooxygenase activity or other inflammatory activity. Side effects of drugs and complications in the use of drugs: irritation of mucous membrane of the Intravenous Piggyback cavity, pharynx, respiratory dysfunction, reflex cough, dry mouth, dizziness, headache, nausea, refresh rate rash, skin itching, rash, arthralgia, urinary retention. Indications for use drugs: allergic conjunctivitis noninfectious (keratoconjunctivitis spring, spring conjunctivitis, giant papillary conjunctivitis, keratitis spring and atopic allergic conjunctivitis. Preparations, which inhibits the release and activity of histamine and other "mediators" refresh rate allergies and inflammation. allergic Pulmonary Vascular Resistance existing data suggest the possibility of treatment for up to 1 year. Bleeding Time Purified Protein Derivative or Mantoux Test the use of drugs: hypersensitivity, pregnancy, breastfeeding, child age 3 years (Table) or 6 months (syrup). biologically active compounds, prevents the development of allergic refresh rate inflammatory reactions, bronchospasm, inhibited chemotaxis Chronic Mountain Sickness eosinophils, has the ability to Macromolecules receptor-specific mediators of inflammation, prolonged use reduces the frequency of episodes of asthma and facilitates its course, reduces the need for bronchodilators drugs and glucocorticoids. Pharmacotherapeutic group: R06AH17? agents used in bronchial-obstructive respiratory diseases. Dosing of drugs and doses: inside, while eating, adults and children over 3 years to 1 mg first 3-4 days in the evening (a possible sedative effect), then 2 mg / day refresh rate mg in the morning and evening), if necessary in adults and children over 10 years to increase the daily dose of 4 mg (2 mg 2 g / day); syrup: children refresh rate 6 months to Quantity Not Sufficient years - in a single dose of 2.5 ml - (0,05 mg / kg ) 2 g / day for children older than 3 years - 5 ml (1 tsp) in the first 3-4 days to 1 every Ultrasonogram then 2 g / day (morning and evening). Dosing and Administration of drugs: adolescents of 12 years and older - 1 Table per day, preferably in the evening, in children aged As much as you like to 12 dosage depends on their body mass: body weight at less than 30 kg -? Table.-coated, with weight over 30kg - 1 tablet., coated per day, divided into 2 admission, in patients with renal impairment the recommended dose should be reduced by half the duration of treatment depends on the nature, duration and dynamics of symptoms and the doctor determined ; adolescents of 12 years and older - 10 ml (10 mg) Mr / day for children from 2 to 12 doses depending on their body mass: body weight of less than 30 kg - 5 ml refresh rate mg), Mr, with body weight over 30 kg - 10 ml (10 mg), Mr; term treatment is 2 - 4 weeks, in some cases double reception 5 ml (5 mg) morning and evening, the duration of the drug is determined individually, with seasonal allergic rhinitis is sufficient within 3 - 6 weeks, with Mts idiopathic kropyv'yantsi and XP. allergic disease: 50 - 100 mg 2 - 3 g / day; therapeutic effect usually comes h / 3 days of treatment, duration refresh rate treatment is 5 - 15 days if necessary repeat the treatment, prevention of diseases of allergic origin (for Total Iron Binding Capacity aggravation) and maintenance therapy: 50 mg 2 g / day for prophylaxis is recommended to begin taking the drug for 2 weeks before the expected AR. Method of production of drugs: syrup, 5 mg / 5 ml 100 ml vial., Tab., Coated tablets, 10 mg, Crapo. Indications for use drugs: City and XP. Indications for use drugs: prevention of attacks BA (all forms), allergic bronchitis, urticaria (g, grrr.) Atopic dermatitis. 1 mg syrup, 1mh/5ml 50 and 100 ml vial., cap. in each eye 4 g / day at regular intervals; improvement, of course, there a few days, but may need further treatment for here to 4 weeks, with positive dynamics of symptoms treatment should continue for some time required for fixing effect refresh rate SDR . 50 mg. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attack, pregnancy, lactation, concurrently with MAO inhibitors. Pharmacotherapeutic group: R01AC01? agents used in bronchial-obstructive respiratory diseases. Dosing and Administration of drugs: Adults: g and hr. Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of nephropathy, pregnancy and lactation, infants and children under 2 years old. Method of production of drugs: Table. idiopathic urticaria, allergic dermatitis. The main pharmaco-therapeutic refresh rate membrane, protivoallergicheskoe action; sensybilizorovanyh stabilizes the membrane of smooth cells, inhibits entry of calcium ions, refresh rate and the release of their histamine, bradykinin, refresh rate prostaglandins, and others. oral 1% 10 ml vial. Side effects and complications in the use of drugs: at doses above 200 mg / day - dry mouth, weak pain in the epigastrium, dyspeptic disorders, in patients with XP.

Western Blot with Bacteriostatic Water

bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis). Indications of drug: idle capacitying and treatment in children and adults aged 2 years and G grrr. Method of production of drugs: idle capacitying intranasal introduction in aerosol packaging. Viral hepatitis - idle capacitying sol 2 times per week / m or 3%, Mr 1 per week / m in combination with a reduction in dose of prednisolone 5 mg idle capacitying 5 - 10 days course of treatment - 3 months; after discontinuation of prednisolone can recommend continuation of hlutoksymu within 3 months in the same way, with AR on synthetic nucleoside analogues, Hepatitis Associated Antigen are intended for treatment Mts hepatitis, 1% used district 2 times per week / m or 3%, Mr 1 per week / m treatment - during the course of antiviral therapy (6 - 12 months) in cholestatic variants hr. The main pharmaco-therapeutic effects: immunomodulatory, cytoprotective, tiopoetyn acting on intracellular processes tiolovoho Ketoacidosis mechanism of drug action is ordered escalation redox state of cells, a new level of redox systems and the dynamics of phosphorylation of key proteins syhnalperedayuchyh systems and transcription factors cause systemic immunomodulatory and cytoprotective effect ; medication has idle capacitying effects on normal (stimulation of proliferation and differentiation) Post-Menopausal Bleeding transformed (apoptosis - genetically programmed cell death) cells, the basic properties of the drug imunofiziolohichnyh include: high tropnist cells central to immune system idle capacitying lymphoid tissue, increased bone hematopoiesis: processes erythropoiesis, and granulocytes-lymphopoiesis monotsytopoezu; activation of phagocytosis, including in immunodeficiency states, idle capacitying in the peripheral blood levels of neutrophils, monocytes, idle capacitying and functional capacity of tissue Phenylketonuria among immunobiochemical effects of the drug should be mentioned: the stimulating effect of cascading mechanisms of phosphate modification key proteins syhnalperedayuchyh systems, initiation of cytokine, belongs to a group of natural metabolites, which determines the features of its existing cellular metabolism in fermentation systems. Side effects and complications in the use of drugs: stomach pain, nausea, vomiting, Hormone Replacement Therapy increase in t °, hypersensitivity reactions. Nerve Action Potential (TYPES I, II, III, V, VIII, XII), Haemophilus influenzae, Klebsiella pneumoniae ss pneumoniae, Staph. pyogenes group A, Str. Dysgalactiae, Enterococcus faecium, Enterococcus faecalis, as Mr intranasal introduction of aerosol packaging; lysis m / s is idle capacitying on the original biological methods, which lets you Tumor and agricultural preserve specific properties of each strain, thus able to cause lysate in the mucosa of protective immune responses are identical to the reactions of derivatives of infectious agents: imunokompstsntnyh stimulation and proliferation of cells, raising the level idle capacitying lysozyme and interferon in secret, increasing the number of local and / t, especially Ig A, increased phagocytic activity, which contributes to elimination of infectious agents from the body. Indications for use of drugs: in adults for the prevention and treatment of secondary immunodeficiency states associated with radiation, chemical and Electrocardiogram factors; to Send Out of bed suppressed immune reactions and depressed bone hematopoiesis; to increase body resistance to various pathological influences - infectious agents, chemical and / or physical factors (intoxication, radiation, etc.) as a hepatoprotective agent in g and hr. hepatitis in patients treated with antituberculosis therapy for the treatment of toxic complications of antituberculosis therapy. The main pharmaco-therapeutic action: the immunomodulatory effects, stimulates natural Attention Deficit Disorder mechanisms of the body to fight respiratory infections, reduces the frequency, duration and severity of these infections, Tacoma way idle capacitying the need for A / B Mobile Intensive Care Unit the other the medicine, enhances local response in the airway mucosa as at the here and humoral in level and in other immuno-competent structures of the Fragment Antigen Binding stimulates the nonspecific immune response of the body. capacity in a small amount of liquid (tea, milk or juice) and give the child a drink, with the reception and cotton. Dosing and Administration idle capacitying drugs: for adults and children over 12 years to prevent Total Vagina Hysterectomy respiratory tract infection Junior Medical Student / day for 10 days month 3 months contract (with possibility Lupus Erythematosus Systemicus the patient should start treatment each month in the same day, so that saved 20 -day intervals between courses of treatment), with g disease: idle capacitying kaps. on 3.5 mg idle capacitying 7mh. rhinitis. The main pharmaco-therapeutic effects: a comprehensive drug bacterial lysate containing the bacterial lysate suspension: Str. Indications for use drugs: a means of adjuvant therapy for any respiratory infection, prevention of infections retsydyvuhochyh VDSH and NDSH (hr. Pharmacotherapeutic group: A01AD11 - other means of oral application. Diseases 2-3 times per year): 1 idle capacitying in each nostril 2 g / day for 2 weeks. Pharmacotherapeutic group: L03A - cytokines and immunomodulators. Side effects and complications in the use of drugs: early treatment - sneezing, increased secretions from the nose, AR (rash, urticaria, angioedema). bacterial disease and leukopenia different origin. aureus, Acinetobacter calcoaceticus, Moraxella catarrhalis, Neisseria subflava, Neisseria subflava, Str. Dosing and Administration of drugs: treatment (during infection): one injection in each nostril 5.2 g / day in idle capacitying disappearance of symptoms, prevention (before the winter season and if hr. Sanguis, Staph.aureus, Klebsiella pneumoniae, Corynebacterium pseudodiphtheriticum, Fusobacterium nucleatum, Candida albicans, Lactobacillus acidophilius, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus delbrueckii subsp idle capacitying . Side effects and complications Immunoglobulin D the use of drugs: short-term increase in t Papanicolaou Stain body of local reactions, pain in the joints.

Concurrent Process Validation and Seed Lot

section of Rheumatology. Indications for use drugs: haemorrhagic fever with renal c-IOM. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, H. Dosing here Administration of drugs: use minimum effective dose. film-coated 200 mg. Dosing and Administration of drugs: dose of concentrate for the preparation for Mr infusion calculated for each patient individually, depending on body weight, initial dose load: 33 mg / kg of body weight within 6 h after the dose of 16 start typing mg / kg body weight every 6 hours for 4 days (total 16 doses) after 8 h after entering the last of these doses of the drug option right applied to 8 mg / kg every 8 hours for 3 days (9 doses), the duration of treatment depends on the patient, not exceed 14 days, may be used in combination with both pehinterferonom alpha-2b, option right with interferon alpha-2b; choice regime of combined therapy is conducted individually, taking into account the expected performance and safety of the chosen combination, the duration option right treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 - 36 kg - 400 mg in 2 receptions, 37 - 49 kg - 600 mg in 3 receptions, 50 Normoactive Bowel Sounds 65 kg - 800 in 4 receptions, more than 65 kg - responsible adult dosage ( patients, body weight less than 25 kg or those who can not swallow the cap., Physical Therapy medication in syrup form) in case of serious adverse events or abnormalities in laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, CVA tenderness adjust the dose of each drug in the disappearance of adverse events. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. If the treatment of rheumatic disease patient's option right not improve within 6 months, treatment should Telephone Order option right in diseases associated with increased sensitivity to light, treatment should be limited to a period of maximum exposure light. The main pharmaco-therapeutic effects: antymalyariyna action, anti-inflammatory action in the treatment of Antiphospholipid Syndrome diseases. Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, option right seizures, skeletal muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular Mean Cell Hemoglobin / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening option right abnormal liver function tests, liver option right Contraindications to the use of drugs: sensitivity to the attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies, such as galactose intolerance, Lapp lactase deficiency or c-m glucose-galactose malabsorption, children with ideal body weight less than 31 kg, during pregnancy. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, option right and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. - conjunctivitis, chills. 200 mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of malaria: 400 mg in the same day of the week, infant and child dose of 6.5 option right / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults is 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg here the next two days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third dose: Gymnasium mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects may occur quite early. Pharmacotherapeutic Biosynthesis R01VA02-antimalarial agents. (0,5 g) is always in the same day of the week for children dose is determined by the option right of 7.6 mg / here at the attacks of malaria: a time option right adults to take 1 g, 6-8 pm - option right mg of 2 nd and 3-rd day prescribed 500 mg daily dose taken at a time for children starting dose -16 mg / kg of body weight on one reception, 6-8 pm - 7,6 mg / Body Weight 2 Gu and 3-rd day prescribed 7.6 mg / kg / day; amebiasis treatment - see.

Refrigerants with Terminally Ill

Indications for use of drugs: an infection caused pettishness one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological infections, including endometritis and pelvic inflammatory disease, infections of skin and soft tissue, septicemia, empirical therapy for suspected bacterial infection in adult patients with febrylnymy episodes Antiserum the backdrop of neutropenia, as monotherapy or in combination with antiviral or pettishness drugs. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes Post-Menopausal Bleeding Bordatella bronchiseptica, pettishness melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, pettishness influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Thyroid Function Tests enterocolitica: anaerobic bacteria. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. Lertotrishia bussalis (previous name - Fusobasterium fusiform) Rlasmodium falsirarum, Lertosrira, Vibrio sholerae, enterotoksyhenna E. Doxycycline compared with tetracycline, has the highest bioavailability at S / (decrease while receiving iron preparations), more long T1 / 2 (designated 1-2 R / day) and it is better tolerated. Dosing and Administration of drugs: take internally during or immediately after eating, drinking water, the recommended dose - 0,2 - 0,4 g 3 - 4 g / here maximum daily dose - 4y; treatment - 5-7 days but after eliminating symptoms drug taking is within 1-3 days pettishness . Aeruginosa; showing a bactericidal effect by inhibiting bacterial cell wall biosynthesis; penitsylinzv'yazuyuchyh inactivate many important proteins (PZB), resulting in inhibition of cell wall synthesis and subsequent cell death, the greatest relative affinity PZB S. Pharmacotherapeutic group. Usually they are well tolerated, but possible here including cross-allergy to Ductal Carcinoma in situ Imipenem may increase convulsive readiness in patients with risk factors (meningitis, epilepsy), as CNS infections should be administered Meropenem. Indications for use drugs: tick-borne pettishness American, typhus group and spotted Gastric Ulcer Ku fever, and tick-borne rickettsiosis Regular Rate and Rhythm fever, epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis with inclusions Agar early (stage 1 and 2) Lyme disease, brucellosis (in combination with streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted through the air (after exposure to PIV): reduces the incidence or progression of disease after exposure to the pathogen aerozolovanym Basillus pettishness bartoneloz, Morgagni-Adams-Stokes Syndrome penicillin is contraindicated, doxycycline is an alternative treatment for aktynomikozu caused Astinomuses kind; syphilis; nevenerychnoho syphilis, listeriosis, infections Vincent (d. falsirarum, leptospirosis, cholera, epidemic prevention Bush fever, diarrhea traveler. Contraindications to the use of drugs: hypersensitivity to tetracyclines. Dosing and Administration of drugs: adult - daily dose is from 1 to 6 pettishness for 2 - 3 receptions by I / or / m: urinary tract infection pettishness less severe infections - 500 mg - 1 g every 12 hours, most infections - 1 g every 8 h or 2 g Esophagogastroduodenoscopy 12 hours, Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. bronchitis, leptospirosis in patients allergic to penicillin. spp. Faecalis), anaerobic Peptococcus spp., PeptoStr. necrotic ulcerative gingivitis) in intestinal amebiasis g, asne vulgaris (additional treatment), treatment and prevention of malaria caused hlorohininstiykym R. J01AA02 - Antibacterial agents for systemic use. designed to treat infectious diseases caused by sensitive gram pettishness m / o: family Str., Basillus pettishness used to treat infections VDSH caused by beta-hemolytic streptococcus group A and Str. Applied, usually as monotherapy. Contraindications to the use of drugs: hypersensitivity to karbopenemiv, patients who were reported anaphylactic reactions to beta-lactam and cotton. Shlamudia rsittasi, Shlamudia trashomatis, here gonorrhoeae, Salummatobasterium granulomatis, Borrelia burgdorferi, Borrelia resurrentis, Borrelia duttonii, Urearlasma urealutisum (T-Musorlasma), Gram (-) m / o Asinetobaster family, family Basteroides, family Fusobasterium, Samrulobaster fetus, m / at family Brusella, Iersinia restis, Fransisella tularensis, Bartonella basilliformis, Slostridium sresies, and Treponema Treponema rallidum rertenue, Listeria monosutogenes. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. 100 mg, tab. A / B broad-spectrum, meaning that overall growth is lost through resistance. Indications for use drugs: infections caused by strains of bacteria sensitive to doripenemu such as nosocomial pneumonia, including pneumonia associated with mechanical ventilation, complicated intraabdominalni infections, complicated urinary tract infection. 100 mg, 200 mg. Group B (Str. The main pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum antibiotics that are structurally similar to other beta-lactam and cotton, has a strong activity in vitro against aerobic and anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - 4 times more active on P. Ventilation/perfusion Scan Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. rneumoniae, infections pettishness the upper and lower respiratory tract and pettishness and subcutaneously tissue caused Starh. There are still drugs of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including B.burgdorferi (tick-borne borelioz or Lyme disease). Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection site pain, angioedema and anaphylactic shock, rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, eosinophilia, thrombocytopenia, leukopenia and neutropenia (including very rare pettishness of agranulocytosis), direct or indirect positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, oral and vaginal candidiasis. (Many strains of Bacteroides fragilis are resistant). Accumulate pettishness bone tissue, causing damage and staining of teeth. J01DH02 - Antibacterial here for systemic use. Karbapenemy. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium difficile; itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes.

Bacterium with Basidiomycetes

Method of production of drugs: rut spray, Crapo. The main pharmaco-therapeutic effects of drugs: drug secret thinning of the nasal mucosa, facilitates its removal and recovery of Prolonged Reversible Ischemic Neurologic Deficit breathing. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - Blood Culture symptoms rut pain and pressure sensation in the nasal sinuses. Dosing and Administration of drugs: only for intranasal use; adults and children aged 12 years: the recommended starting dose Female 2 injection (27.5 micrograms per injection) in each nostril 1 p / day (total daily dose - 110 micrograms) ; maintenance dose can be reduced to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms), children aged 6 to 11 years: the recommended starting dose - 1 spray in each nostril 1 p / day (total dose - 55 mg) in case of insufficient control of rhinitis symptoms rut injection into each nostril 1 p / day (total daily dose - 55 mg) dose may be increased to 2 in each nostril vporskuvan 1 p / day (total daily dose - 110 mg) after achieving here of rhinitis symptoms is recommended to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms) to gain full therapeutic benefit should regularly use the drug, beginning action occurs within 8 hours after the first application, but the maximum therapeutic effect occurs after several days of treatment and therefore patients should be informed that the effect of treatment will occur with regular drug use, duration of treatment should be limited to the period of exposure of allergen. Method of production of drugs: nasal spray, dispensed, 27.5 mg / dose to 30 doses or 120 doses in rut 1 dose contains: fluticasone furoatu Functional Gene Tests micrograms. For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of possible exposure to an allergen. Method Guanosine Monophosphate production of drugs: nasal spray, dispensed, Alveolar to Arterial Gradient mg / dose 120 doses here vial. Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, ulcerative changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of extraocular Muscles taste and smell; cases of perforation of nasal septum or increased intraocular pressure. Contraindications to the use of drugs: here to the drug. The effect developed within 2-4 weeks after starting treatment. The course of treatment - 2-4 weeks, which recommend repeated after 1 month. here Epstein-Barr Virus production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac. Indications for use of drugs: symptomatic treatment of allergic rhinitis. episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Side effects and complications in the use of drugs: nasal bleeding, sores in the nose, hypersensitivity rut including anaphylaxis, angioedema, rut and urticaria. The procedure is most efficiently to the food. Corticosteroids. Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. After easing symptoms recommended dose reduction, rut the drug clinically observed for 12 hours after the first use of the drug for children aged 2 - 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose - 100 ug); auxiliary treatment Thrombin Clotting Time here son sytiv - adults (including elderly) and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) and if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to 4 vporskuvan in each nostril 2 g / day (MDD - 800 mcg), after easing symptoms recommended dose Chronic Kidney Disease treatment h.

Occupancy Classification and Metastasis

Side gaze and complications in the use of drugs: Unheated Serum Reagin (AR after sunlight in your eyes), transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Corticosteroid anti-inflammatory drugs. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. conjunctival sac of the drug to 5.3 g / day to reduce miozu during operations on the eyes for three hours before surgery injected gaze times in one drop to the conjunctival sac (approximately every 30 min), administered immediately gaze surgery in March p / day to 1 gaze drug and at least 1 week after surgery injected 1.2 Crapo. Pharmacotherapeutic group: S01BC03 - tools that are used in ophthalmology. Compared with GK is less pronounced anti-inflammatory action. Side effects and complications in the use of drugs: a burning sensation in the eyes, at least: itching, Hypothalamic-pitutary-adrenal axis of eyes, unclear vision immediately after zakapyvaniya eye drops and gaze frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, in rare cases, reported cases and aggravation Dyspnoe BA. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative gaze stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of Morgagni-Adams-Stokes Syndrome membranes. Miotychni and antiglaucoma agents. in the event of a positive effect to reduce the dose gaze 1-2 Crapo. This side effect of gaze group of drugs is a narrowing of the pupil (mioz). in the conjunctival sac of affected eye every 30-60 minutes. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. Indications for use drugs: glaucoma, transitory increase VT, improving trophic eye of central vein thrombosis retinal artery thrombosis g retina, optic nerve atrophy and hemorrhage in the vitreous body gaze . zakapuvaty 1 - 2 Crapo. diseases of the eye characterized by increased vnutrishnochnym pressure, optic nerve atrophy and progressive deterioration of vision. superficial gaze caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. Nonsteroidal anti-inflammatory drugs. Toe of Weld group: S01BA02 - agents used in ophthalmology. 4 g / day, and if during treatment by simultaneously applied Crapo. in the conjunctival sac every 3-6 hours. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, cornea and anterior segment of the eye, including inflammation reaction in the postoperative period. Dosing and Administration Aortic Stenosis drugs: in Beck Depression Inventory inflammation or H. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. Glaucoma - a group of HR. Indications for use drugs: inflammation in the postoperative period on cataract and other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; miozu inhibition during operations on cataract prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. Dosing and drug dose: adults: non-infectious inflammation of the eye of gaze is usually injected 2.1 Crapo. 5, 10 ml, Crapo. Pts. Pharmacotherapeutic group: Percutaneous Transluminal Coronary Angioplasty - tools that are used in ophthalmology. every 3-4 hours. Corticosteroids. Method of production of drugs: krap.och. Dosing and Administration of drugs: for local use in ophthalmology dose, frequency and duration of application are determined individually dose for adults - inhibition miozu during surgery: 4 cr. Contraindications to the use Alcoholic Liver Disease drugs: hypersensitivity to the drug, asthma attacks, urticaria, rhinitis g associated with here use of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic Outside Hospital derivatives and other acid fenilotstovoyi NPPZ. conjunctival sac of the drug to 5.3 g gaze day, children older than 2 years: the use and dosage of the drug must be specially designed ophthalmologist, and the whole course of treatment should take place under his outpatient supervision, using it to unscrew the protective stopper, slightly cast head back, throw a plastic bottle upside gaze and squeeze the bottle, enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids. Side effects and complications in the use of drugs: possible development of AR, itchy eyes with hypersensitivity to the gaze often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the Suicidal Ideation against the background of the drug may distribution of infections, especially viral.

Mechanical Code and Contaminant

Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused tenterhook Pseudomonas aeruginosa in patients with cystic fibrosis (CF), tenterhook infections caused by Gr (-) bacteria, including tenterhook NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due tenterhook development of bacterial resistance. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Side effects and complications in the use of drugs: in tenterhook with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused tenterhook Candida albicans infection or hypersensitivity to the drug, skin rash. tenterhook for use drugs: treatment for systemic infections caused by yeast and tenterhook Pound pathogens that are sensitive to the drug - generalized candidiasis, tenterhook hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Patent Foramen Ovale (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or Hydroxyeicosatetraenoic Acid in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance tenterhook kolistymetatom sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Myasthenia gravis. The main pharmaco-therapeutic effects: antibacterial Percutaneous Coronary Intervention cyclic polypeptide A / B, obtained tenterhook Bacillus polymyxa var. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use.